title: Zanamivir (Relenza )--a new treatment for influenza.
abstract: Deaths from influenza are recorded every year in the UK and flu epidemics raise concerns for the safety of the young, the elderly and other vulnerable groups in the community. Not surprisingly, the launch of zanamavir (Relenza) by Glaxo Welcome (Middlesex, UK) has received much attention in the medical media and lay press. Just who should receive this treatment and under what conditions it should be given remains to be confirmed in practice.
authors.forename: A M
authors.initials: AM
authors.lastname: MacConnachie
mesh_terms: D000367:Age Factors; D000368:Aged; D000998:Antiviral Agents / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use*; D002648:Child; D011307:Drug Prescriptions; D006146:Guanidines; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000453:epidemiology; D018579:Patient Selection; D011634:Public Health; D011714:Pyrans; D012794:Sialic Acids / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use*; D006113:United Kingdom; D014611:Vaccination; D053243:Zanamivir
chemical_list: D000998:Antiviral Agents; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D053243:Zanamivir